Early Ruxolitinib Initiation Increases Spleen Response Rates in Myelofibrosis
Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.
Related Articles
Social Determinants of Health Significantly Affect Some Psychoneurological Symptoms in Breast Cancer Survivors
Social factors including financial needs and stress caused increased levels of psychoneurological symptoms in breast cancer survivors.
Subcutaneous Nivolumab Sustains Comparable Efficacy, Safety to IV Formulation in Advanced ccRCC
Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.
Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC
ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.
FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications
The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.
FDA Approves Larotrectinib for NTRK-Positive Solid Tumors
The FDA has granted full approval to larotrectinib for select patients with solid tumors harboring a NTRK gene fusion.
Intravenous Sirolimus Shows Tolerability, Early Efficacy in Malignant PEComa
Phase 1b data support further exploration of intravenous sirolimus in patients with malignant PEComa.
Expanded FDA Approval Broadens the Role of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC
Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.
Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC
Osimertinib plus Dato-DXd elicits responses in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib.
Dr Jacob on the Potential for TAR-200 to Shift the Treatment Paradigm in NMIBC
Joseph Jacob, MD, MCR, discusses how emerging data for TAR-200 could represent a shift in the treatment paradigm for patients with high-risk non–muscle-invasive bladder cancer.
Insights Into Marginal Zone Lymphoma
Catherine Thieblemont, MD, PhD, and Paola Ghione, MD, MSEpi, discuss insights into marginal zone lymphoma.